The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

Inclusion Criteria: * Provide written informed consent; * Body weight ranging from 50 to 100 kilograms (kg) \[110 to 220 pounds\] and body mass index (BMI) of 18 to 30 (kg/m2); * Males and females aged 18 to 50 years; * Willing to eat the food supplied during the study; * Willing to refrain from strenuous exercise through the end-of-study visit. Subjects did not begin a new exercise program nor participate in any unusually strenuous physical exertion; * Healthy and free of significant abnormal findings as determined by medical history, physical examination, clinical laboratory values, vital signs, and safety 12-lead ECG; * Females of childbearing potential must use an adequate and reliable method of contraception (ie, barrier with additional spermicidal foam or jelly, intra-uterine device, hormonal contraception). Females who are postmenopausal must be postmenopausal for ≥ 1 year and have elevated serum follicle stimulating hormone (FSH). Exclusion Criteria: * Females who are pregnant (positive beta human chorionic gonadotropin test) or lactating; * Current or recent (within 5 years) history of drug or alcohol abuse; * History or any current conditions that may interfere with drug absorption, distribution, metabolism, or excretion; * Use of an opioid-containing medication in the past 30 days preceding the initial dose in this study; * Known allergy to hydrocodone, opioids, psychotropic or hypnotic drugs, moxifloxacin, or any member of the quinolone class drugs; * Any history of frequent nausea or emesis regardless of etiology; * Any history of seizures or head trauma with sequelae; * Participation in a clinical drug study during the 30 days preceding the initial dose of study drug in this study; * Use of any medication including thyroid hormonal therapy (hormonal contraception and hormonal replacement therapy in the form of estrogen with or without progestin is allowed), vitamins, herbal and/or mineral supplements during the 7 days preceding the initial dose of study drug; * Any significant illness during the 30 days preceding the initial dose of study drug in this study; * Any personal or family history of prolonged QT interval or disorders of cardiac rhythm; * Abnormal cardiac conditions including hypertension; * Abnormal cardiac condition denoted by any of the following: * QT data corrected for heart rate using the Fridericia formula (QTcF) interval \>450 milliseconds (msec) * PR interval \>240 msec or QRS \>110 msec * Evidence of second- or third-degree atrioventricular block * Pathological Q-waves (defined as Q-wave \>40 msec or depth \>0.5 millivolts \[mV\]) * Evidence of ventricular pre-excitation, complete left bundle branch block (LBBB), right bundle branch block (RBBB), or incomplete RBBB * With a resting heart rate (HR) outside the range of 40 to 90 beats per minute (bpm); * Abnormalities on physical examination, vital signs, safety 12-lead ECG, or clinical laboratory values, unless those abnormalities are judged clinically insignificant by the investigator; * Oxygen saturation \<94% as measured by pulse oximetry (SpO2); * Refusal to abstain completely from caffeine or xanthine during confinement; * Refusal to abstain from consumption of alcoholic beverages 48 hours prior to initial study drug administration through the end-of-study visit; * Blood or blood products donated within 30 days prior to initial study drug administration or any time through the end-of-study visit, except as required by the study protocol; * History of smoking or use of nicotine products within 45 days of initial study drug administration or a positive urine cotinine test; * Positive results of urine drug screen or alcohol screen; * Positive results of hepatitis B surface antigen (HBsAg), hepatitis C antibody (anti-HCV); * Presence of Gilbert's Syndrome or any known hepatobiliary abnormalities; * The investigator believes the subject to be unsuitable for reason(s) not specifically stated in the exclusion criteria.